Beth baber oen science summit

762 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
762
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • NED, No Evidence of Disease.
  • NED, No Evidence of Disease.
  • In the US, ~1.4 million adults are diagnosed with cancer each year compared to ~13,000 children. Childhood cancer is the leading cause of death in children by a disease, killing more children than asthma, diabetes, CF and AIDS combined. In 2007, National Cancer Institute (NCI) provided $4.8 Billion in cancer research grants. However, the childhood cancer only received $172 Million in research grants, only 3.5% of NCI funds. $41 Million of the $172 Million in childhood cancer research funds is awarded to the National Childhood Cancer Foundation to assist the Children’s Oncology Group in performing clinical trials.
  • Through TACTiC, TNCI value is derived from being able to bridge the gap between the research done at other research institutions and clinical application.
  • TNCI through TACTiC will significantly reduce R&D cost for pediatric oncology products through the physical sharing of available resources with our industry partners (e.g. collaborative grants, space, equipment, reagents, etc.). Our industry partnerships will be in the following domians: Genomics, Proteomics, Bioinformatics, Molecular Diagnostics (Dx), Drug Development, Companion Diagnostics (Dx), Immunotherapy, Vaccine Development, Nanotechnology and Wireless Technology. These domains are necessary research components of understanding, diagnosing and treating disease. Assuming most non-profits research institutions are operating with over 80% in indirects, TACTiC automatically saves $23 Million. TNCI will submit its first wave of non-profit/for-profit collaborative grants in August 2009 with Prognosys Bioscience and AltheaDx. As these grants are funded, we will establish TNCI laboratories within these companies and share available resources to move the identified technology forward. One biomedical industry partnership will be established every year for the first 5 years.
  • TNCI through TACTiC will significantly reduce R&D cost for pediatric oncology products through the physical sharing of available resources with our industry partners (e.g. collaborative grants, space, equipment, reagents, etc.). Our industry partnerships will be in the following domians: Genomics, Proteomics, Bioinformatics, Molecular Diagnostics (Dx), Drug Development, Companion Diagnostics (Dx), Immunotherapy, Vaccine Development, Nanotechnology and Wireless Technology. These domains are necessary research components of understanding, diagnosing and treating disease. Assuming most non-profits research institutions are operating with over 80% in indirects, TACTiC automatically saves $23 Million. TNCI will submit its first wave of non-profit/for-profit collaborative grants in August 2009 with Prognosys Bioscience and AltheaDx. As these grants are funded, we will establish TNCI laboratories within these companies and share available resources to move the identified technology forward. One biomedical industry partnership will be established every year for the first 5 years.
  •   TNCI Board of Directors:   Beth Alton is Founder and President of Keene Solutions. Keene Solutions provides outsourced human resource support, management coaching, training and advises non-profit clients on board governance issues.  Beth spent nearly 20 years in the non-profit, bio-research sector with the Salk Institute for Biological Studies in La Jolla, CA. Her most recent role was that of Vice President, Human Resources.    Beth Anne Baber, Ph.D. has over 20 years of academic experience. Her current research at The Salk Institute focuses on the understanding of the molecular mechanisms involved in DNA damage repair. Her work has led to publications in major scientific journals, including Nature and Science . Beth is the 2007 DLA Piper-Athena FlexMBA Scholarship recipient and expected to receive her MBA from UCSD Rady School of Management in August 2009.     Bud Bromley has a track record of entrepreneurial leadership spanning 3 decades. Bud is the President and COO is Psynomics, Inc., a company dedicated to developing tests and software for diagnosis and drug response for psychiatric diseases. Bud has been senior business development, marketing and sales executive at four public corporations, each a startup or young company supplying high technology instrumentation, software, consumables and services for life sciences and chemical analysis.   Mort Freedman has been in real estate since 1966. Mort founded Nationwide Resources Corporation in Tucson, AZ. Mort also served for ten years on board of the Jewish Federation and served for 11 years on the board of the Steele Memorial Children's Research Centre. During his tenure at the Steele, Mort has overseen the growth of a nascent research-focused organization to a well-funded and fully integrated research center for pediatric children disease.   Tony Hunter, Ph.D. is Director of the Molecular and Cell Biology Laboratory at the Salk Institute and Director of the Salk Institute Cancer Center. He has received numerous awards for his scientific contributions, including a National Cancer Institute Outstanding Investigator Award, the General Motors Cancer Research Foundation Mott Prize, the Biochemical Society Hopkins Medal, the Keio Medical Science Prize, the American Cancer Society Medal of Honor, the Landon-AACR Prize for Cancer Research. He is a Fellow of the Royal Society of London, an Associate Member of the European Molecular Biology Organization (EMBO), a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Sciences and a Member of the Institute of Medicine.   Martin Latterich, Ph.D. is Sr. Director of research and Development for Biomatrica. Martin has over fifteen years of industrial and academic experience in pharmacogenomics, proteomics, and the biochemistry of proteins and small molecules. He held a faculty appointment jointly between the University of Montreal, Faculty of Pharmacy, and the Montreal Heart Institute’s Pharmacogenomics Center. Additionally, Martin served on the faculty of McGill University and the Salk Institute. He has also held senior management and executive positions at several biotechnology companies, including Illumina, Inc. Martin serves as consultant to VC firms, pharmaceutical, and biotechnical companies.   Geoffrey M. Wahl, Ph.D . is a Professor at the Salk Institute and an Adjunct Professor in the Department of Biology at UCSD. Geoff was elected to and served as President of American Association for Cancer Research (AACR) for the Centennial year, 2007 and he continues to be very active in his role as Past President. In the broader scientific community, he has served on numerous special science conference and committee posts, and has been a member of the editorial boards of numerous journals.   John Wooley , Ph.D. is Associate Vice Chancellor of Research at UCSD. John created the first government research funding programs in bioinformatics and computational biology. He is also an Adjunct Professor at the university, in Pharmacology, Chemistry and Biochemistry, and a strategic advisor and Senior Fellow of the San Diego Supercomputer Center. For the new UCSD California Institute for Telecommunication and Information Technology, Wooley directs the biology and biomedical applications component, termed Digitally-enabled Genomic Medicine, a step in delivering personalized medicine in a wireless clinical setting. Jeff Wolf, RCC is founder of Wolf Management Consultants. Jeff has built a valued practice that speaks to key problems confronting businesses today. Jeff is known as one of America’s most dynamic speakers , is considered one of the top executive business coaches in the country, and is a highly sought after management consultant. Jeff was a former CEO of one of the country’s largest healthcare receivables management companies and a prestigious polling and political opinion research corporation involved in strategic decisions for congressional, senatorial and presidential races. Jeff’s new book, Roadmap to Success , with management gurus Ken Blanchard and Stephen Covey has just been released and his second book, The Essence of Effective Leadership , debuts soon. David Geerdes, is an Attorney at Law and former Of Counsel of Procopio Cory Hargreaves & Savitch. David was a Management Attorney for Gray Cary Ware & Freidenrich and Heller Ehrman, LLP. David was appointed by the Mayor of San Diego to serve on the Commission on Financing the Infrastructure. In addition to many other commission appointments, David was the Legal Advisor to Board of Trustees and Executive Committee for the Salk Institute and general counsel for the San Diego Convention and Visitors Bureau.   Janet Vohariwatt is a CEO and founder of iChanneX Corporation. Prior to founding iChanneX, she served as VP Global Product Development at Inasoft and VP of SAIC, Xerox Corporation, and Ford Aerospace Telecom Subsidiary-Starnet. Janet has led teams in developing innovative IT solutions for customers such as Kaiser Permanente, Saskatchewan Provincial Health, Department of Defense Health Services, and BellSouth Wireless among many others. Janet serves in the Sharp HealthCare Foundation Board of Directors, and support in UCSD Rady Mentor Program.
  • Beth baber oen science summit

    1. 2. By translating biomedical discoveries into an integrated, personalized treatment program for children with cancer By developing cancer-specific predictive tests to guide cancer therapy for each child By bringing to the clinic new therapies that considers the unique molecular physiology of the child and their cancer THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research Our Mission is to meet this disease head on with better detection, diagnostic tools and kid friendly treatments that bring hope to all those involved…
    2. 3. THE NICHOLAS CONOR INSTITUTE Date of Dx: 7/19/05 High-Risk Neuroblastoma Combinatorial Chemotherapy, Surgery & Retinoic Acid Therapy NED: 2 ½ years post treatment for Pediatric Cancer Research What kind of treatments option does a child like Conor have? Beth Anne Baber, Ph.D., Co-founder, President and CEO Mother of Nicholas “Conor” Boddy “ Not very many. Radiation was not an option … surgery was not an option. The only thing left was high intensity chemotherapy. Often children with his condition are given 10X the adult dose of chemotherapy that obviously leads to long-term side effects … You may not see these effects immediately, these long-term side- effects will occur as they grow into adulthood.” -Beth Anne Baber, Conor’s Mom Burrill Report Patient Perspective Podcast July 2009
    3. 4. THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research <ul><ul><li>87,000 will die from the disease/yr worldwide </li></ul></ul><ul><ul><li>Survivors will suffer from the long-term, side-effects </li></ul></ul><ul><ul><li>Treatment choices are few and unpredictable </li></ul></ul><ul><ul><li>Rarity of individual childhood cancers discourages </li></ul></ul><ul><li> expensive commercial research and development </li></ul>The facts are … <ul><ul><li>1 out of 300 children will be diagnosed before age 20 </li></ul></ul><ul><ul><li>Worldwide ~160,000 are diagnosed/yr. </li></ul></ul>The facts are … but we can make an impact
    4. 5. Unacceptable Market Reality SITUTATION: If the projected revenue is <$800 M/yr, then NO new pediatric oncology drug development. CURRENT STRATEGY: Piggyback onto adult products for the lack of pediatric targeted therapies AND often give the children 10X the adult dose. PROBLEM: Small market and modest overlap between adult & childhood cancers. CURRENT COST: ~ $500,000 to >$2,500,000 to treat each child Leukemia (30%) Brain & NS (22.3%) Lymphomas (8%) Neuroblastoma (7.3%) Other cancers (32.4%)
    5. 6. Our advantage is the value we create Develop Validate Apply Baseline 6 months to 1 year Acquire Identify Technology & Industry Partner(s) TNCI Value Creation Time Horizon: 2-5 years Translate Research (Other Institutions) Time Clinic
    6. 7. TACTiC reduces R&D cost through sharing of resources. TACTiC creates mini centers of excellence for childhood cancer in the biomedical industry. TACTiC TM : Non-profit Strategy for Innovation TACTiC is flexible and scalable T he A ccelerator of C ancer T reatments i n C hildren Clinical application <ul><li>Obtain funding </li></ul><ul><li>Government </li></ul><ul><li>Foundation </li></ul><ul><li>Philanthropy </li></ul>Molecular Dx Company Identify industry partner Commercialize or Identify Partner Establish on-site laboratory Molecular Dx Company
    7. 8. TACTiC TM iChanneX & GenVault TBA TBA Prognosys BioSc & others TBA AltheaDx CollabRx & others TBA Industry Partners: Genomics Proteomics Bio- informatics CDx MDx Centers of Excellence for Childhood Cancer: The Nicholas Conor Institute Academia Children’s Oncology Group & Clinical Research Centers International Consortiums Pediatric Cancer Outcome Exchange
    8. 9. TACTiC TM : Non-profit Strategy for Innovation <ul><li>The advantages of TACTiC TM are many: </li></ul><ul><ul><li>Quick start-up with built in capacity; </li></ul></ul><ul><ul><li>Provides a focused effort to translate key academic discoveries to the clinic; </li></ul></ul><ul><ul><li>Direct transfer of knowledge and expertise between industry and academia; </li></ul></ul><ul><ul><li>Economies of scale, sharing of infrastructure and capital equipment leads to lowers indirect cost; </li></ul></ul><ul><ul><li>Efficient use of research dollars appeals to funding organizations and donor investors; </li></ul></ul><ul><ul><li>Appeals to research institutes that license their discoveries for commercialization; </li></ul></ul><ul><ul><li>Allows for flexibility and easily scalable; and, </li></ul></ul><ul><ul><li>Aligns with our mission and differentiates The Nicholas Conor Institute from others. </li></ul></ul>
    9. 10. The Nicholas Conor Institute’s Strategic & Patient Advocacy Partners <ul><li>Children’s Rare Disease Network (CRDN, The Project) </li></ul><ul><li>Public awareness for children’s rare diseases, including Childhood Cancer </li></ul><ul><li>Cure Search for Children’s Cancer </li></ul><ul><li>(National Childhood Cancer Foundation, NCCF) </li></ul><ul><li>Support for Children’s Oncology Group </li></ul><ul><li>Support for TNCI personalize medicine initiatives </li></ul><ul><li>Public awareness for childhood cancer, the need for industry involvement, </li></ul><ul><li>and a personalize approach the treating childhood cancer </li></ul>
    10. 11. THE NICHOLAS CONOR INSTITUTE Board of Directors Beth Alton Chair of the Board of Directors Founder and CEO of Keene Solutions Beth Anne Baber, Ph.D., MBA Co-founder and CEO Martin Latterich, Ph.D. Co-founder and CSO John Wooley, Ph.D. Assoc. Vice Chancellor of Research-UCSD Geoff Wahl, Ph.D. Professor at the Salk Institute Former President of the AACR Trustee of the AACR Foundation Tony Hunter, Ph.D. Prof. & Director of the Salk Institute Cancer Center Bud Bromley President and COO of Psynomics Mort Freedman Former Chair of Steele Children’s Research Center Jeff Wolf Founded and CEO of Wolf Management Consultants Janet Vohariwatt Founder and CEO of iChanneX David Geerdes Attorney at Law
    11. 12. THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research TheNicholasConorInstitute.org (TNCI.org)

    ×